Brought to you by 
Roche and NeoImmuneTech to test combination therapy in skin cancers
25 Oct 2021
Executive Summary
Roche agreed to conduct a combination study of its Tecentriq (atezolizumab) with NeoImmuneTech Inc.’s HyLeukin-7 (IL-7-hyFc) in three high-risk skin cancers: melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche and NeoImmuneTech to test combination therapy in skin cancers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice